Equity Research case studies, worked step by step
- Cases
- 100
- Traced to a firm
- 30
- Topics
- 12
- Hard
- 30
Topic
Showing 51–60 of 70 · filtered from 100Clear filters
- 077An electronics maker beats consensus EPS by 10%, but operating cash flow is negative, receivables jumped Rs 300 crore and there is a one-off export incentive. Was it a real beat?Sell-side equity researchHedge fund long/short
- 078Build next year's revenue for a quick commerce company growing from 400 to 700 dark stores, where each new store takes six months to reach 1,500 orders a day.Sell-side equity researchIndian brokerage research
- 079Value an EV charging network that loses money until year four. In one scenario it scales to Rs 600 crore of free cash flow; otherwise it is sold cheaply. How do you build one value?Buy-side equity researchHedge fund long/short
- 080A cement company looks cheap on P/E against its peers but trades in line with them on EV/EBITDA, and it carries net debt of three times EBITDA. Which multiple should you trust, and why?Sell-side equity researchBuy-side equity research
- 081An NBFC with Rs 20,000 crore of loans sees gross NPAs rise from 2% to 4.5% and keeps provision cover at 55%. What does that do to credit cost and ROE this year?Sell-side equity researchIndian brokerage research
- 082An IT services company with USD 500 million of revenue wins a USD 300 million five-year deal that ramps over 12 months at a margin 6 points below its average. What does it do to growth and margin next year?Sell-side equity researchIndian brokerage research
- 083A software company capitalises 45% of its R&D while peers capitalise 10%. Restate its EBITDA margin and free cash flow on a peer basis.Hedge fund long/shortSell-side equity research
- 086A group is demerging its consumer arm, which peers value at 30x EBITDA, from its chemicals arm, valued at 12x. The group trades at 14x. How much value could the split unlock?Sell-side equity researchIndian brokerage research
- 087A retailer that is a 3% position falls 18% in a day on one quarter's same-store sales miss, 2% against 7% expected. Do you add, hold or cut, and what evidence decides it?Multi-manager podHedge fund long/short
- 089A pharma company cuts growth guidance from 12% to 7%. Your EPS estimate falls from Rs 48 to Rs 43 and the stock drops 15% from Rs 960 to Rs 816. How much of the cut is already priced in?Sell-side equity researchHedge fund long/short
Company names and figures are illustrative.
